fda stance on compounded semaglutide The has received reports of adverse events after patients used versions of semaglutide. Some compounders may also be using unapproved salt forms., Patients should avoid compounded FDA Warns Against Using Compounded

Semaglutide carries a class label warning regarding rodent thyroid C-cell tumors and is contraindicated in individuals with personal or family history of medullary thyroid carcinoma or MEN 2

This is one area where the long-term benefits of semaglutide may actually outweigh the short-term indirect risks from side effects

Pieber TR, Bode B, Mertens A, et al

this too could be attenuated by UA 36

Furthermore, investigating patient-specific factors, including genetic predispositions and disease progression variability, will be critical for understanding the full therapeutic potential of GLP-1RAs and optimizing personalized treatment strategies for diabetes-related cognitive dysfunction

And if you're not taking medication, you're still getting great all-around care and superb results